Exelixis
EXEL
#1319
Rank
โ‚น1.554 T
Marketcap
โ‚น6,372
Share price
-0.31%
Change (1 day)
68.71%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น323.41

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น322.85. In 2025 the company made an earnings per share (EPS) of โ‚น269.67.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น323.4119.93%
2025โ‚น269.67
2023โ‚น60.9614.61%
2022โ‚น53.19-22.97%
2021โ‚น69.05100%
2020โ‚น34.52-65.09%
2019โ‚น98.91-53.91%
2018โ‚น214.61333.96%
2017โ‚น49.45-260.61%
2016-โ‚น30.79-58.75%
2015-โ‚น74.65-42.45%
2014-โ‚น129.705.3%
2013-โ‚น123.17

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น623.29 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น66.25-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,622 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น184.80-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น92.66-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น421.76 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น268.49-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น1,327-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น78.38-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA